Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...

The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.

Functional neurologist Dr. Lars Landers opens a new Wellesley clinic and launches restorative-neuro.com, a measurement-guided neurorehabilitation practice. People who have already been through ...

Most Americans with cerebral palsy are now adults, but the care system built for children leaves them with chronic pain and ...

High intake of ultra-processed foods is associated with an increased risk for cognitive impairment, particularly in adults younger than 60 years.

Axsome Therapeutics (AXSM) stock gains as the FDA accepts the company's marketing application for its narcolepsy therapy ...

A noninvasive neuromodulation technology has received Breakthrough Device Designation from the U.S. Food and Drug ...

Modern, human-made environments that feature certain design elements can overload the brain, causing visual discomfort and ...

The brain-first versus body-first model proposes that Lewy body disease can originate from different pathogenic routes, accounting for heterogeneity in symptoms, neurodegeneration patterns and ...

BRAIN, an open-source AI scientist deploying three free computational tools to accelerate Alzheimer's drug discovery.

New studies point to the power of testing for and treating tau, a protein that builds up in Alzheimer’s disease, instead of ...

Evidence supports cannabis-based therapies for a limited number of conditions. Here’'s what clinicians should know — and tell ...